10 Jun 2022 11:21
PRESS RELEASE
Results of 2022 Annual General Meeting
Guildford, 10 June 2022: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today. All Resolutions were duly passed.
Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:
Resolution number | Resolution | Votes for | Votes against | Abstentions |
1 | Accounts | 40,070,518 | 0 | 1,492,956 |
2 | Reappoint auditor | 41,493,555 | 69,125 | 794 |
3 | Reappoint John Dawson | 41,454,634 | 107,895 | 945 |
4 | Reappoint Mark Enyedy | 34,200,041 | 7,362,488 | 945 |
5 | Reappoint Michael Spiteri | 32,439,508 | 9,123,278 | 688 |
6 | Allot securities | 39,399,013 | 2,163,803 | 658 |
7 | Pre-emption rights | 39,808,724 | 1,754,493 | 257 |
8 | Pre-emption rights | 39,699,675 | 1,863,542 | 257 |
9 | Amendment to Articles of Association | 41,563,066 | 0 | 408 |
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com
Ergomed's Board engage with the Company's shareholders and other stakeholders to understand their views. Whilst all resolutions were passed, shareholders representing over 20% of votes cast voted against Resolution 5 and the Board will re-engage with them to better understand their position.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.